series-c-plus
Stage
1
Investors
About
LumaCyte develops label-free, real-time, microfluidic single-cell analysis instruments using Laser Force Cytology™ to quantitatively characterize cells without antibody or genetic labeling, supporting advanced biologics, cell and gene therapy development, and bioprocess monitoring.
Explore LumaCyte's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.